TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Health impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive and negative mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical symptom 2 days after medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiology study 3 days and one week after medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly level of health enhancing physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically defined delayed cerebral ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Native myocardial T1 relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Supine Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure of pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The FLACC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hearing Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Corneal Epithelial Immune Dendritic Cell Density (Central Cornea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Corneal Epithelial Immune Dendritic Cell Density (Inferior Cornea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Corneal Epithelial Immune Dendritic Cell Density (Nasal Cornea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Corneal Epithelial Immune Dendritic Cell Density (Superior Cornea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Corneal Epithelial Immune Dendritic Cell Density (Temporal Cornea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Concentrations Against Protein D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vision Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in phonemic fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cumulative occurrence of ICD shocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient perceived quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in opioid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in self-reported injection status via Timeline Followback
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ALT, AST and GGT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV-DNA serum load < 500 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of Factor VIII issued
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total dose of Factor IX issued
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lin's Concordance correlation coefficient (CCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device Survival
Endpoint domain: Mortality/survival
Primary endpoint: delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal Pain/Abdominal Discomfort Weekly Responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Irritable Bowel Syndrome (IBS) Degree of Relief Responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants with passing grades in an OSCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marks attained in an OSCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health outcomes in aging childhood cancer survivors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in mandibular length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of cognitive testing and validated questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of anterograde colonic motor patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cranio Cervical Flexion test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of scapular dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep Neck Flexor Endurance Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV Ribonucleic acid (RNA) viral load reduction from baseline during the 24hr and post-dosing following a single dose of GSK2336805 in HCV subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HCV RNA change from baseline to nadir (maximum change) in HCV subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time course of HCV viral load at baseline, after dosing with GSK2336805, and for greater than or equal to 2 weeks after GSK2336805 dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of beta cell reserves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Severity of histological rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rankin Score (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety and tolerability of AZD2281
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative blood sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Vancouver Scar Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in DNA sequence of the 16S rRNA gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Weight at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline waist circumference at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Glycated hemoglobin at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of high grade dysplasia and carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With Improved Clinical Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aGVHD-free survival
Endpoint domain: Mortality/survival
Primary endpoint: graft failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Inter-rater agreement measured by weighted Kappa score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between triage level and hospitalisation rate
Endpoint domain: Mortality/survival
Primary endpoint: Activity Counts Per Minute (CPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trends in personal and social situations of vulnerability in TRHIV
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Trends in obstacles encountered in medical care and healthcare needs
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Facial irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Compliance percentage to therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Persistence percentage of therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence percentage to therapy, assessed prospectively
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Myocardial Fat Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic Fat Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline Fear of Spiders Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline Spider Behavioral Approach Task Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceleration based movement characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gonorrhea and Chlamydia Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline High Resolution Esophageal Manometry With Impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Influx Constant (Ki) for 18F-FDOPA PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 11C-DASB PET Binding Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Elasticity Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUCτ) of Infliximab at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of Disease Activity Score Using 28 Joint Counts (DAS28) (CRP) at Week 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of serum sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of subjects with fever
Endpoint domain: Adverse events/effects
Primary endpoint: Immune response measured by RRV-specific IgG titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in MADRS-6 subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Histological HSIL clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma DCA (Microgram/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Half Lives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Maleylacetone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma concentration of parent drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter-related blood stream infections density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Mouth Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Interferon Beta-1a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Neopterin and MxA Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of retinal function of the macula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Normalization of Abnormal Tympanometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean running time of haemodialysis circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Interferon-Gamma Spot Forming Units (IFN-gamma SFUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Corneal transparency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart beating rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: partial oxygen saturation pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of tooth loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from symptoms to diagnosis of autoimmune diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Dwell Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggregate Mean Difference in Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Continuous Insulin Monitoring Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse within first 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Seroconversion rate of antibody against group A, C polysaccharide meningitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate of antibody against type b haemophilus influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Early development of right heart dilation and failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute difference between systolic blood pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain activity in cortical and subcortical areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of women who are amenorrheic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of ovulation detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of women who would use the urine luteinizing hormone tests again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with adverse events for etoricoxib
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events for H56:IC31 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events for combined etoricoxib and H56:IC31 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of respiratory infections
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients needing a Second Surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mRNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrioventricular synchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral cholinergic nicotinic receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acceptance of Offer to Join Stop Smoking Program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety and tolerability measured through Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability measured through lab measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability measured through ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability measured through physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI safety measurement through biomarker analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in convulsive seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of CT Based FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of CT Based FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: eradication of bacterial and/or fungal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: clinical outcome of COVID-19 patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of non-reassuring fetal heart rate tracings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: number of oocytes in metaphase II obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Economic differences between treatment methods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: qualified referrals to development office
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in CDR-SOB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of first severe clinical exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the Hear Glue Ear application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Migration of pN stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Boston Carpal Tunnel Syndrome Questionnaire (BCTQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hand grip strength (HGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross-Sectional Area of the Median Nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ability to regress neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of adverse drug reactions and severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in severity of dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall nutritional quality of the shopping cart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection rate of the appendix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Microvascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dynamics of vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dynamics of cathelicidin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absence of recurrent pulmonary embolism (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absence of inferior vena cava (IVC) thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in NIHSS at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Documented Decisions to Forgo Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Autoantibodies targeting brain antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Apoptosis measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased extraction of blood-borne ketone bodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolomic signatures in heart failure blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe and unexplained hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Concentration (Cmax) of alisporivir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time-concentration curve (AUC) for alisporivir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiome characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of catheter related deep venous thrombosis or catheter occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fidelity to the intervention model
Endpoint domain: Delivery of care